Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ascendis Pharma ADR (NQ: ASND )

117.74 -5.76 (-4.66%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 276,550
Open 124.22
Bid (Size) 47.12 (2)
Ask (Size) 121.60 (1)
Prev. Close 123.50
Today's Range 116.49 - 124.65
52wk Range 61.58 - 134.53
Shares Outstanding 56,937,682
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Week In Review: Qitan Raises $101 Million For Nanopore Sequencing Devices
Qitan Technology, a Chengdu nanopore sequencing company, completed a $101 million Series C round to support its commercialized nanopore devices. Meanwhile, Japan’s Takeda was approved to launch... 
Via Talk Markets
Where Ascendis Pharma Stands With Analysts
 
Via Benzinga

Performance

YTD
-2.47%
-2.47%
1 Month
-2.47%
-2.47%
3 Month
-1.70%
-1.70%
6 Month
+28.61%
+28.61%
1 Year
-2.27%
-2.27%

More News

Read More
What 9 Analyst Ratings Have To Say About Ascendis Pharma
Via Benzinga
Analyst Ratings for Ascendis Pharma
Via Benzinga
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
Ascendis Pharma's Program Hits Primary Goal In Children With Short-Limbed Dwarfism
Via Benzinga
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Hasbro, Ascendis Pharma, Coinbase Global And Some Other Big Stocks Moving Lower On Monday
Via Benzinga
Analyst Ratings for Ascendis Pharma
Via Benzinga
6 Analysts Have This to Say About Ascendis Pharma
Via Benzinga
Expert Ratings for Ascendis Pharma
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022
Via Benzinga
Ascendis Seeks FDA Nod For TransCon PTH In Adults With Hypoparathyroidism
Via Benzinga
Expert Ratings for Ascendis Pharma
Via Benzinga
What 14 Analyst Ratings Have To Say About Ascendis Pharma
Via Benzinga
Oppenheimer Maintains Outperform Rating for Ascendis Pharma: Here's What You Need To Know
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Via Benzinga
Ascendis Slammed After Growth Hormone Drug Faces An Unexpected Challenge
Via Investor's Business Daily
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
Via Benzinga
BofA Upgrades Ascendis Pharma After Promising TCP Phase 3 Data
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
10 Biggest Price Target Changes For Monday
Via Benzinga
Ascendis Pharma's Hypoparathyroidism Trial Meets Primary, Secondary Endpoints
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.